Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
10 03 2020
10 03 2020
Historique:
received:
06
12
2019
accepted:
24
01
2020
revised:
17
01
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to study such factors that can help identify patients at a higher risk of relapse or death. This retrospective study included 79 patients who underwent first HCT for myelofibrosis at three centers between 2005 and 2016. Univariate analysis showed that red blood cell (RBC) transfusion dependence (HR 9.02, 95% CI 4.0-20.35), platelet transfusion dependence (HR 8.17, 95%CI 3.83-17.37), 100% donor chimerism in CD33 + cells (HR 0.21, 95%CI 0.07-0.62), unfavorable molecular status (HR 4.41, 95%CI 1.87-10.39), normal spleen size (HR 0.42, 95%CI 0.19-0.94), grade ≥ 2 bone marrow fibrosis (vs. grade ≤ 1; HR 2.7, 95%CI 1.1-6.93) and poor graft function (HR 2.6, 95%CI 1.22-5.53) at day +100 were statistically significantly associated with relapse-free survival (RFS). RBC transfusion dependence and unfavorable molecular status were also statistically significant in the multivariate analysis. Patients in whom both of these factors were present had a significantly worse RFS when compared to those with one or none. While limited by a small sample size, we demonstrate the significance of transfusion dependence and molecular status at day +100 in predicting outcomes.
Identifiants
pubmed: 32157091
doi: 10.1038/s41408-020-0302-9
pii: 10.1038/s41408-020-0302-9
pmc: PMC7064504
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Subventions
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Références
Haematologica. 2019 Jul 11;:
pubmed: 31296578
Biol Blood Marrow Transplant. 2016 Jul;22(7):1206-1211
pubmed: 26970380
Exp Hematol. 2006 Dec;34(12):1617-23
pubmed: 17157157
Leuk Lymphoma. 2014 Feb;55(2):450-2
pubmed: 23682558
Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97
pubmed: 24161923
Blood. 2010 Nov 4;116(18):3572-81
pubmed: 20489052
Blood. 2014 Aug 14;124(7):1183-91
pubmed: 24963042
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
J Clin Oncol. 2011 Feb 1;29(4):392-7
pubmed: 21149668
Blood. 2005 May 1;105(9):3493-501
pubmed: 15665119
Biol Blood Marrow Transplant. 2013 Aug;19(8):1152-8
pubmed: 23571461
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Leuk Lymphoma. 2002 Apr;43(4):719-24
pubmed: 12153156
Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151
pubmed: 30625392
Blood. 2009 Feb 19;113(8):1866-8
pubmed: 19228938
Haematologica. 2019 Sep;104(9):1782-1788
pubmed: 30733269
Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101
pubmed: 28389256
Haematologica. 2012 Oct;97(10):1574-81
pubmed: 22491742
PLoS Med. 2006 Jul;3(7):e270
pubmed: 16834459
Blood. 2012 Mar 15;119(11):2657-64
pubmed: 22234678
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Bone Marrow Transplant. 2019 Feb;54(2):204-211
pubmed: 29795431
Bone Marrow Transplant. 2010 Sep;45(9):1404-7
pubmed: 20062088
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Blood. 2009 Dec 17;114(26):5264-70
pubmed: 19812383
Biol Blood Marrow Transplant. 2014 Jun;20(6):812-5
pubmed: 24589549